chevron_leftBack
As of 6 June 2026, Invion Ltd. has a market cap of $4.29M USD, ranking #45013 globally and #1625 in Australia.
It ranks #3984 in the Healthcare sector, and #1280 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$4.29MUSD
6.01M AUD
Enterprise Value
$4.81MUSD
6.74M AUD
EBITDA (TTM)
-$3.68MUSD
-5.16M AUD
Net Income (TTM)
-$7.49MUSD
-10.5M AUD
PB Ratio
1.1
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Thian Chew
open_in_new
Employees
3
Founded
2000
Website
inviongroup.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0% | 1.6% | -17% | -33% | -33% | -44% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
IVX
Invion Ltd
ISIN: AU000000IVX4
Shares Out.:
Shares Outstanding:
96.965M1
Shares Float:
58.277M2
|
0.0620 AUD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Invion Ltd.
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer. The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr. I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
ASX: SIG
|
$22.82B
532K%
31.98B AUD
|
52.3
|
|
ASX: PYC
|
$926.22M
21K%
1.3B AUD
|
-
|
|
ASX: RAC
|
$346.24M
8K%
485.18M AUD
|
-
|
|
ASX: CUV
|
$335.4M
8K%
469.99M AUD
|
14.5
|
|
ASX: SPL
|
$216.39M
5K%
303.23M AUD
|
-
|
|
ASX: MYX
|
$166.4M
4K%
233.18M AUD
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
18M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
13M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
8M%
|
97.4
|
|
SIX: RO
|
$324.68B
8M%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$289.43B
7M%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$277.35B
6M%
218.9B CHF
|
20.5
|
chevron_leftBack